CGC Canopy Growth
Data as of close
Healthcare · Medicinal Chemicals & Botanical Products
Canopy Growth (CGC) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $288 million. Shares last traded at $0.68, 71.3% below their 52-week high. Over the past year the stock is down 44.6%. Net profit margin is -80.0%, below the peer median of -8.8%. Revenue grew 5.8% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Canopy Growth reports in CAD: EPS, dividends and financials are shown in CAD as filed. P/E, P/S, P/B and yield convert them at 1 CAD = 0.7165 USD on 2026-10-30 (Federal Reserve H.10 via FRED, DEXCAUS).
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL, reported in CAD.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | -CA$0.03 | 2026-08-07 |
| Q4 2026 (derived) | -CA$0.45 | 2026-06-15 |
| FY 2026 | -CA$0.88 | 2026-06-15 |
| Q3 2026 | -CA$0.17 | 2026-02-06 |
| Q2 2026 | -CA$0.02 | 2025-11-07 |
| Q1 2026 | -CA$0.24 | 2025-08-08 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Medicinal Chemicals & Botanical Products peers
CGC vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close
| DFTX | Definium Therapeutics, Inc. | $4.4B | — | — | — | -10.70% |
| RGC | Regencell Bioscience Holdings Ltd | $3.1B | — | — | — | -5.00% |
| TRLV | Trulieve Cannabis Corp. | $2.1B | — | 1.88 | -41.8% | +8.19% |
| CRON | Cronos Group | $1.2B | 17.64 | 6.89 | 39.1% | +1.52% |
| TLRY | Tilray Brands | $375M | — | 0.39 | -17.1% | +0.40% |
| SNDL | SNDL Inc. | $337M | — | — | — | +2.81% |
| CGC | Canopy Growth | $288M | — | 1.37 | -80.0% | +4.07% |
| USNA | USANA HEALTH SCIENCES INC | $271M | — | 0.30 | -2.4% | +2.69% |
| ACB | Aurora Cannabis | $237M | — | — | — | +3.94% |
| GLAS | Glass House Brands Inc. | $192M | — | 1.05 | -16.3% | +6.85% |
| NAGE | Niagen Bioscience, Inc. | $190M | 11.88 | 1.47 | 12.4% | +2.56% |
| MDWD | MediWound Ltd. | $173M | — | — | — | +1.35% |
| FTLF | FITLIFE BRANDS, INC. | $78M | 12.45 | 0.77 | 6.2% | +4.69% |
| BTMD | biote Corp. | $33M | 5.56 | 0.18 | 3.2% | +1.79% |
Source: SEC EDGAR (fundamentals/EPS/dividends, reported in CAD) · Databento EQUS.MINI (prices) · FX: 1 CAD = 0.7165 USD on 2026-10-30 (Federal Reserve H.10 via FRED, DEXCAUS) · market cap & yield computed by tradmap. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.